Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
All-in-one AAV-mediated Nrl gene inactivation rescues retinal degeneration in Pde6a mice
Zhiquan Liu, Siyu Chen, Chien-Hui Lo, Qing Wang, Yang Sun
Zhiquan Liu, Siyu Chen, Chien-Hui Lo, Qing Wang, Yang Sun
View: Text | PDF
Research Article Ophthalmology Therapeutics

All-in-one AAV-mediated Nrl gene inactivation rescues retinal degeneration in Pde6a mice

  • Text
  • PDF
Abstract

Retinitis pigmentosa (RP) is a complex group of inherited retinal diseases characterized by progressive death of photoreceptor cells and eventual blindness. Pde6a, which encodes a cGMP-specific phosphodiesterase, is a crucial pathogenic gene for autosomal recessive RP (RP43); there is no effective therapy for this form of RP. The compact CRISPR/Staphylococcus aureus Cas9 (CRISPR/SaCas9) system, which can be packaged into a single adeno-associated virus (AAV), holds promise for simplifying effective gene therapy. Here, we demonstrated that all-in-one AAV-SaCas9–mediated Nrl gene inactivation can efficiently prevent retinal degeneration in a RP mouse model with Pde6anmf363/nmf363 mutation. We screened single-guide RNAs capable of efficiently editing the mouse Nrl gene in N2a cells and then achieved effective gene editing by using a single AAV to codeliver SaCas9 and an optimal Nrl-sg2 into the mouse retina. Excitingly, in vivo inactivation of Nrl improved photoreceptor cell survival and rescued retinal function in treated Pde6a-deficient mice. Thus, we showed that a practical, gene-independent method, AAV-SaCas9–mediated Nrl inactivation, holds promise for future therapeutic applications in patients with RP.

Authors

Zhiquan Liu, Siyu Chen, Chien-Hui Lo, Qing Wang, Yang Sun

×

Figure 3

Preservation of retinal photoreceptors in Pde6a mice by Nrl gene inactivation.

Options: View larger image (or click on image) Download as PowerPoint
Preservation of retinal photoreceptors in Pde6a mice by Nrl gene inactiv...
(A–C) Representative immunofluorescence images of retinal sections in Nrl-edited or Pde6a control mice at P60. HA (A), rhodopsin (B) and cone arrestin (C) indicate SaCas9 expression, rod photoreceptors, and cone photoreceptors, respectively. Scale bar, 50 μm. (D) Quantification of the fluorescence intensities of HA, rhodopsin, and cone arrestin in Nrl-edited or Pde6a control mice at P60. Data are shown as the mean ± SEM and n = 3 biologically independent experiments. All P values were calculated by 2-sided t tests. *P < 0.05, **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts